Healthcare Pharmaceuticals

What Healthcare Pharmaceuticals does

Healthcare Pharmaceuticals Limited (HPL) is a Bangladesh-based, privately-held pharmaceutical manufacturer founded in 1996 that develops, produces, and markets branded generic medicines across 47+ therapeutic categories — including analgesics, antibacterials, antidiabetics, cardiovascular, CNS, oncology, gastrointestinal, and vitamin/mineral products — in multiple dosage forms (tablets, capsules, injections, pre-filled syringes, oral solutions, suspensions, eye drops, sachets, topical). Its portfolio comprises 630+ registered medicines and 270+ generic products, manufactured at a GMP-compliant plant in Gazipur built with technical guidance from F. Hoffmann-La Roche Limited (Basel). The company serves healthcare providers — hospitals, clinics, pharmacies, and physicians — primarily in Bangladesh through a dedicated sister-concern distributor (Healthcare Distribution), while exporting to 32+ countries across Asia, Africa, the CIS, the Middle East, and the Americas via its International Business Department. The corporate group includes wholly-owned subsidiaries covering formulations (Healthcare Formulations), chemicals (Healthcare Chemicals), life sciences (Healthcare Life Science), diagnostics (Healthcare Diagnostic Solutions and Healthcare Diagnostic Center), and dairy/food (Shelaidah Dairy, Healthcare Dairy & Food Products). HPL has stated a 24% annual growth rate, employed over 7,800 people, and received the Kano-BSTQM Quality Award (KBQA) in April 2026 — a first for Bangladesh — recognizing manufacturing quality. Revenue mechanics are prescription-based, country-by-country pharmaceutical distribution; pricing is not publicly disclosed and the company is privately held with no disclosed funding rounds, parent company, or external PE/VC ownership.

Name

Healthcare Pharmaceuticals

Legal name

Healthcare Pharmaceuticals Limited

Website

https://hplbd.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Healthcare Pharmaceuticals Limited is a Bangladesh-based private manufacturer of branded generic pharmaceuticals, producing 630+ registered medicines across 47+ therapeutic categories at a GMP plant built with Roche guidance, serving domestic healthcare providers and exporting to 32+ countries.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)

Keywords

• Branded generic pharmaceuticals
• Pharmaceutical manufacturing
• Generic medicines
• GMP certified manufacturing
• Pharmaceutical formulations

Headquarters

HQ city

Dhaka

HQ country

Bangladesh

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Branded Generic Pharmaceuticals: Development, manufacturing, and marketing of branded generic pharmaceutical products across multiple therapeutic categories including analgesics, antibiotics, cardiovascular, antidiabetic, CNS, and oncology products

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Healthcare Pharmaceuticals Limited manufactures and markets branded generic pharmaceutical products across 47 therapeutic categories — including analgesics, antibacterials, antidiabetics, cardiovascular, CNS, oncology, antacids, and vitamins — in multiple dosage forms such as tablets, capsules, injections, pre-filled syringes, oral solutions, eye drops, and sachets. The company operates GMP-compliant manufacturing facilities and exports to 32+ countries through enterprise sales and dedicated distribution channels.

Product overview

Healthcare Pharmaceuticals Limited (HPL) is a Bangladesh-based pharmaceutical manufacturer producing branded generic medicines across 47 therapeutic categories and multiple dosage forms. The product portfolio spans Analgesic/Antipyretic, Antibacterial, Antidiabetic, Cardiovascular, Respiratory, CNS (Antipsychotic, Antidepressant, Antiepileptic, Anxiolytic), Oncology, Gastrointestinal (Antacid, Antiulcerant), Vitamin & Mineral supplements, and more. Featured products include Felitan (NK3 receptor antagonist), Marcus (neuropathic pain), Kenzo (PPI), and the recently launched Clacido antibiotic line. The company operates GMP-certified manufacturing facilities with technical guidance from F. Hoffmann-La Roche, exporting to 32+ countries worldwide with over 630 registered medicines.

Differentiator

Problem solved

Functional benefit

Products and services

• Felitan® Fezolinetant-based NK3 receptor antagonist medication for the treatment of menopausal symptoms.
• Marcus® Mirogabalin-based medication for the treatment of neuropathic pain conditions.
• Lygen-V Multivitamin supplement combined with L-Lysine for nutritional support.
• Kenzo Vonoprazan-based proton pump inhibitor (PPI) for the treatment of acid-related disorders.
• Cisplat® Cisplatin-based anticancer chemotherapy medication.
• Lyric® Pregabalin-based medication for epilepsy, anxiety, and neuropathic pain.
• Syndol® Tramadol-based analgesic for moderate to severe pain management.
• Clacido® Amoxicillin + Clavulanic Acid combination antibiotic for treating bacterial infections including respiratory tract, urinary tract, and skin infections, available as tablets, injection, and powder for suspension.
• Neopenem Meropenem-based carbapenem antibiotic for serious multi-bacterial infections.
• Edvila-M Vildagliptin + Metformin combination for Type 2 diabetes management.
• Evaglip Empagliflozin + Linagliptin combination for Type 2 diabetes with dual mechanism of action.
• Latuda® Lurasidone Hydrochloride for the treatment of schizophrenia and bipolar depression.
• Ransys AM® Olmesartan Medoxomil & Amlodipine Besilate combination for hypertension management.
• Abicon® Sodium Alginate & Potassium Bicarbonate formulation for acid reflux and heartburn relief.
• Ticoplan Teicoplanin glycopeptide antibiotic for serious gram-positive infections.
• Denvar Cefixime-based cephalosporin antibiotic for respiratory and urinary tract infections.
• Furotil Cefuroxime-based cephalosporin antibiotic with beta-lactamase inhibitor.
• Zoli® Oxymetazoline Hydrochloride nasal drops for nasal congestion relief.
• Welzinc® Zinc Sulfate Monohydrate supplement for zinc deficiency treatment.
• D-Vine Cholecalciferol (Vitamin D3) supplement for bone health and calcium absorption.
• Myorel® Baclofen-based muscle relaxant for spasticity management.
• Aeron Montelukast for asthma and allergic rhinitis treatment.
• Bondrova® Ibandronate Sodium for osteoporosis treatment.
• Hyalgun® Sodium Hyaluronate for joint lubrication and osteoarthritis treatment.
• Alexa Enoxaparin Sodium low molecular weight heparin for anticoagulation therapy.
• Vorifast Voriconazole for the treatment of serious fungal infections.
• Tegalon® Tigecycline injection for complicated skin infections, intra-abdominal infections, and community-acquired pneumonia.
• Rocipro® Ciprofloxacin-based quinolone antibiotic for urinary, respiratory, and gastrointestinal tract infections.

Quantifiable outcome

• 7800+ employees driving operations
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Faculty of Pharmacy, University of DhakacoreStrategic or Co-development Partner · 23 December 2025Strategic MoU signed for collaboration in pharmaceutical research, development, and academic partnership. Aims to strengthen the link between industry and academia for pharmaceutical innovation.
• F. Hoffmann-La Roche LimitedcoreStrategic or Co-development PartnerTechnical guidance and assistance from Roche experts to establish world-class GMP-compliant manufacturing facility in Bangladesh. Roche provided advice for establishing pharmaceutical manufacturing conforming to global Good Manufacturing Practices standards.
• TillyminorStrategic or Co-development PartnerPartnership with global MNC for international market access and brand positioning.
• MSDminorStrategic or Co-development PartnerPartnership with global MNC for international market expansion and collaborative opportunities.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Eskayef Pharmaceuticals: Bangladesh-based subsidiary of Transcom Group producing branded generics with strong export operations to Asia and Africa. Eskayef's product mix and emerging-market export profile directly overlap with HPL.
• ACME Laboratories: Bangladesh-based pharmaceutical manufacturer with branded generics across multiple therapeutic categories and growing export operations. ACME is a peer of similar scale and product breadth competing in the same domestic and export markets.
• ACI Limited: Bangladesh conglomerate with significant pharmaceutical operations producing branded generics for domestic and export markets. ACI competes with HPL across similar therapeutic categories and Bangladesh distribution channels.
• Square Pharmaceuticals: Bangladesh's largest pharmaceutical company, also a branded generic manufacturer with extensive domestic market share and growing exports. Square is the most direct comparable in scale, therapeutic breadth, and export geography to HPL.
• Renata Limited: Bangladesh-based pharmaceutical and animal health company with branded generics across human therapeutics. Renata competes directly with HPL in the domestic market and similar export geographies.
• Beximco Pharmaceuticals: Leading Bangladesh-based branded generic manufacturer with FDA-approved generics sold in the US and strong emerging-market exports. Beximco's product portfolio, therapeutic breadth, and export focus closely mirror HPL's model.
• Incepta Pharmaceuticals: Top-tier Bangladesh pharmaceutical manufacturer specializing in branded generics with significant export footprint across Asia, Africa, and Latin America. Incepta's scale, portfolio, and emerging-market focus make it a near-direct peer.

Broad incumbents

• Cipla: Indian multinational generic pharmaceutical giant with deep emerging-market presence across Africa and Asia. Cipla is a much larger incumbent competitor in the same therapeutic categories and export geographies HPL serves.
• Lupin Limited: Indian pharmaceutical major with a strong branded generics presence in emerging markets including Asia and Africa. Lupin's product range and geographic footprint overlap materially with HPL's export strategy.
• Dr. Reddy's Laboratories: Indian multinational with a sizable branded generics business in emerging markets (Russia/CIS, Africa) and a strong generics pipeline. Dr. Reddy's competes with HPL in CIS and African export markets where HPL is growing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Healthcare Pharmaceuticals